BridgeBio Oncology Therapeutics EBIT

The latest EBIT for BBOT is $-200M as of June 2026. That compares with $-120B in the prior-year period — up 99.8% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside BridgeBio Oncology Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BBOT's EBIT moved from $-120B to $-200M — a 99.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BridgeBio Oncology Therapeutics's operating scale or balance-sheet position.

Against its sector companies, BBOT currently prints $-200M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at BridgeBio Oncology Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-200M for BBOT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting BBOT's EBIT ($-200M), review year-over-year change from $-120B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.